• Celldex Therapeutics Inc., of Needham, Mass., completed accrual for its Phase IIb (EMERGE) trial of CDX-011 (glembatamumab vedotin) for metastatic breast cancer. The drug targets glycoprotein NMB (GPNMB). The randomized, controlled trial enrolled heavily pre-treated breast cancer patients unlikely to benefit from any approved therapies and whose tumors express GPNMB. Endpoints include response rate and progression-free survival. The trial is being carried out at 20 sites within the U.S.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter